Astrazeneca's Beyfortus receives EU approval
Sharecast
Published Nov 04, 2022 07:10
Updated Nov 04, 2022 07:41
Astrazeneca's Beyfortus receives EU approval
AstraZeneca (NASDAQ:AZN) stated that Beyfortus was now the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or pre-term, or with specific health conditions.
The FTSE 100-listed group said the European Commission was the first regulatory body to grant approval to Beyfortus, with the approval based on results from the drug's clinical development programme and follows a recommendation from The Committee for Medicinal Products for Human Use of the European Medicines Agency in September.
In AZN's "pivotal" MELODY efficacy trial, Beyfortus met its primary endpoint of reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% versus placebo through day 151 with a single dose.
Iskra Eric, AZN's executive vice president of vaccines and immune therapies, said: "Beyfortus is the first single-dose preventative option against respiratory syncytial virus to gain approval in Europe and is also the first and only preventative option approved for a broad infant population.
"Today's marketing authorisation of Beyfortus marks a significant achievement for the scientific community and addresses a persistent, global unmet need in RSV prevention."
Reporting by Iain Gilbert at Sharecast.com
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.